Chloroquine for influenza prevention: A randomised, double-blind, placebo controlled trial

The Lancet Infectious Diseases

Volumn 11, Issue 9, 2011, Pages 677-683

  Paton, Nicholas I ^a   Lee, Lawrence ^a   Xu, Ying ^b,c   Ooi, Eng Eong ^c,d   Cheung, Yin Bun ^b,c   Archuleta, Sophia ^a   Wong, Gerard ^a,e   Smith, Annelies Wilder ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d DSO NATIONAL LABORATORIES   (Singapore)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; INFLUENZA VACCINE; PLACEBO; RNA;

ADULT; ARTICLE; BLOOD SAMPLING; BLURRED VISION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEMAGGLUTINATION; HEPATITIS; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFORMATION SERVICE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE SMEAR; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SORE THROAT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHLOROQUINE; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NASAL CAVITY; RNA, VIRAL; SELF REPORT; YOUNG ADULT;

EID: 80051819215     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70065-2     Document Type: Article

References (29)

1. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452.
2. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010, 2. CD001265.
3. Oshitani H, Kamigaki T, Suzuki A Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008, 14:875-880.
4. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 2003, 3:722-727.
5. Ooi EE, Chew JS, Loh JP, Chua RC In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006, 3:39.
6. Di Trani L, Savarino A, Campitelli L, et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 2007, 4:39.
7. Vigerust DJ, McCullers JA Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses 2007, 1:189-192.
8. Fedson DS Confronting an influenza pandemic with inexpensive generic agents: can it be done?. Lancet Infect Dis 2008, 8:571-576.
9. Fedson DS Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009, 15:365-371.
10. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12:1203-1207.
11. Division of AIDS table for grading severity of adult adverse experiences 1992, Division of AIDS N, National Institute of Allergy and Infectious Diseases, Rockville.
12. WHO manual on animal influenza diagnosis and surveillance 2002, WHO, World Health Organization, Geneva.
13. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
14. Fouchier RA, Bestebroer TM, Herfst S, Van Der Kemp L, Rimmelzwaan GF, Osterhaus AD Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol 2000, 38:4096-4101.
15. Wang R, Sheng ZM, Taubenberger JK Detection of novel (swine origin) H1N1 influenza A virus by quantitative real-time reverse transcription-PCR. J Clin Microbiol 2009, 47:2675-2677.
16. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999, 341:1336-1343.
17. Welliver R, Monto AS, Carewicz O Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001, 285:748-754.
18. Ng TP, Pwee KH, Niti M, Goh LG Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singapore 2002, 31:182-188.
19. Fraser C, Donnelly CA, Cauchemez S Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324:1557-1561.
20. Greenwood B Interpreting vaccine efficacy. Clin Infect Dis 2005, 40:1519-1520.
21. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis; 4: e785.
22. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996, 18:1080-1092.
23. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993, 9:91-98.
24. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001, 15:2221-2229.
25. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005, 2:69.
26. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997, 19:913-923.
27. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995, 17:622-636.
28. Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br J Clin Pharmacol 1995, 39:696-699.
29. Ducharme J, Farinotti R Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet 1996, 31:257-274.